Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study

• Verfasst von: Lückemeier, Philipp [VerfasserIn]
• Verfasst von: Radujković, Aleksandar [VerfasserIn]
• Verfasst von: Holtick, Udo [VerfasserIn]
• Verfasst von: Kurch, Lars [VerfasserIn]
• Verfasst von: Monecke, Astrid [VerfasserIn]
• Verfasst von: Platzbecker, Uwe [VerfasserIn]
• Verfasst von: Herling, Marco [VerfasserIn]
• Verfasst von: Kayser, Sabine [VerfasserIn]
• Titel: Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study
• Verf.angabe: Philipp Lückemeier, Aleksandar Radujkovic, Udo Holtick, Lars Kurch, Astrid Monecke, Uwe Platzbecker, Marco Herling and Sabine Kayser
• E-Jahr: 2023
• Jahr: 23 June 2023
• Umfang: 12 S.
• Fussnoten: Gesehen am 23.08.2023
• Titel Quelle: Enthalten in: Frontiers in oncology
• Ort Quelle: Lausanne : Frontiers Media, 2011
• Jahr Quelle: 2023
• Band/Heft Quelle: 13(2023), Artikel-ID 1208028, Seite 1-12
• ISSN Quelle: 2234-943X
• DOI: doi:10.3389/fonc.2023.1208028
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1857684281

Abstract

Background: Post-transplant lymphoproliferative disorders (PTLD) are heterogeneous lymphoid disorders ranging from indolent polyclonal proliferations to aggressive lymphomas that can arise after solid organ transplantation (SOT) and allogeneic hematopoietic transplantation (allo-HSCT). Methods: In this multi-center retrospective study, we compare patient characteristics, therapies, and outcomes of PTLD after allo-HSCT and SOT. Twenty-five patients (15 after allo-HSCT and 10 after SOT) were identified who developed PTLD between 2008 and 2022. Results: Median age (57 years; range, 29-74 years) and baseline characteristics were comparable between the two groups (allo-HSCT vs SOT), but median onset of PTLD was markedly shorter after allo-HSCT (2 months vs. 99 months, P<0.001). Treatment regimens were heterogeneous, with reduction of immunosuppression in combination with rituximab being the most common first-line treatment strategy in both cohorts (allo-HSCT: 66%; SOT: 80%). The overall response rate was lower in the allo-HSCT (67%) as compared to the SOT group (100%). Consequently, the overall survival (OS) trended towards a worse outcome for the allo-HSCT group (1-year OS: 54% vs. 78%; P=0.58). We identified PTLD onset ≤150 days in the allo-HSCT (P=0.046) and ECOG >2 in the SOT group (P=0.03) as prognostic factors for lower OS. Conclusion: PTLD cases present heterogeneously and pose unique challenges after both types of allogeneic transplantation.